Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, daratumumab (Darzalex®) cannot be endorsed for use within NHS Wales in combination with bortezomib, melphalan and prednisone for the treatment of adults with newly diagnosed multiple myeloma who are not suitable for stem cell transplant. |
||
|
||
Medicine details |
||
| Medicine name | daratumumab (Darzalex®) | |
| Formulation | 20 mg/ml concentrate for solution for infusion | |
| Reference number | 2821 | |
| Indication | In combination with bortezomib, melphalan and prednisone for the treatment of adults with newly diagnosed multiple myeloma who are not suitable for stem cell transplant. |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 28/03/2019 | |